Bristol Myers takes a swing at 'off-the-shelf' cell therapies in $150M cash licensing pact with Century

Last to the game in the current generation of CAR-T cell therapies, Bristol Myers Squibb has wasted no time trying to challenge its closest rivals’ …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bris­tol My­ers takes a swing at 'off-the-shelf' cell ther­a­pies in $150M cash li­cens­ing pact with Cen­tu­ry